Theorem Clinical Research, Charles River Form Alliance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Theorem Clinical Research, Charles River Form Alliance



The CRO, Theorem Clinical Research has formed an alliance with the CRO, Charles River Laboratories that will provide clients with an integrated solution from nonclinical testing and analysis through clinical development and registration. The new alliance provides nonclinical testing programs in the areas of bioanalysis, immunogenicity, and immunology to support clinical trials.

Charles River’s research models, preclinical testing capabilities and clinical support services are backed by a bioanalysis portfolio for non-GLP and GLP programs. Laboratories are equipped with instrumentation to measure drug and metabolite concentrations in biological matrices and to provide support for capillary micro- sampling and dried blood spot analysis.

Source: Theorem Clinical Research

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here